Table 4.

Conversion to AD in the different MCI biomarker-based subgroups

	Using Aβ42, t-Tau and p-Tau for classification	Using Aβ42/40 ratio, t-Tau and p-Tau for classification
LL	4/40 (10%)	3/38 (8%)
IAP	7/16 (44%)	8/18 (44%)
SNAP	20/36 (56%)	9/17 (53%)
HL	39/52 (75%)	50/71 (72%)

Data are expressed as n/total (percentage) of patients

AD Alzheimer’s disease, MCI mild cognitive impairment, Aβ42 42-aminoacid isoform of amyloid beta, t-Tau total Tau protein, p-Tau hyperphosphorylated Tau protein, Aβ40 40-aminoacid isoform of amyloid beta, LL low-AD likelihood, IAP isolated amyloid pathology, SNAP suspected non-Alzheimer pathology, HL High-AD likelihood